American Society of Hematology Annual Meeting

Anti-CD38 antibodies poised to transform myeloma treatment

Posted on: 05/01/2015 - 17:46

SAN FRANCISCO – Combining anti-CD38 monoclonal antibodies with standard antimyeloma therapies proved highly active without excessive toxicity in new... More »

Field of Interest: Oncology

Type: News Item

Game-changing study could end exclusion for HIV-related lymphomas

Posted on: 08/12/2014 - 20:17

SAN FRANCISCO – Autologous hematopoietic stem cell transplantation should be offered to patients with HIV-related lymphomas and treatment-responsive HIV infection, results from a new study...

Field of Interest: Oncology

Type: News Item

Brentuximab changes landscape for post-transplant Hodgkin’s lymphoma patients

Posted on: 07/12/2014 - 17:32

SAN FRANCISCO – Early post-transplant brentuximab vedotin dramatically slows Hodgkin’s lymphoma progression in patients at high risk for relapse or progression, the phase III AETHERA study...

Field of Interest: Oncology

Type: News Item

Anti-CD38 antibodies poised to transform myeloma treatment

Game-changing study could end exclusion for HIV-related lymphomas

Brentuximab changes landscape for post-transplant Hodgkin’s lymphoma patients

Newsletters

Latest Newsletters

You are here

American Society of Hematology Annual Meeting

Anti-CD38 antibodies poised to transform myeloma treatment

Game-changing study could end exclusion for HIV-related lymphomas

Brentuximab changes landscape for post-transplant Hodgkin’s lymphoma patients

Newsletters

Latest Newsletters